Nirmatrelvir (Synonyms: PF-07321332)

Name: Nirmatrelvir
Brand: MedChemExpress
SKU: HY-138687
Rating: 5.0 (103 reviews)

Cat. No.: HY-138687 Purity: 99.74%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Nirmatrelvir (PF-07321332) is a potent and orally active SARS-CoV 3C-like protease (3CL^PRO) inhibitor. Nirmatrelvir (PF-07321332) targets to the SARS-CoV-2 virus and can be used for COVID-19 research.

For research use only. We do not sell to patients.

CAS No. : 2628280-40-8

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 103 publication(s) in Google Scholar

Other Forms of Nirmatrelvir:

103 Publications Citing Use of MCE Nirmatrelvir

Bio/Physico-chemical Assay

In Vivo Efficacy Study

Histological Imaging/Staining

In Vivo Imaging

Cell Proliferation/Viability Assay

: Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 3;16(1):2900. [Abstract]; Mice were treated at 6 h, 24 h and 48 h with euthanasia performed at 72 h post-infection. WT 7-9 week-old mice were infected with SARS-CoV-2 P21 and treated with either vehicle, PLT (Paxlovid-like treatment: 56 mg/kg Nirmatrelvir, 19 mg/kg Ritonavir), or WEHI-P8 (100 mg/kg or 150 mg/kg). Three days post-infection, mice were monitored for d viral load and percentage change in body weight compared to initial body weight.

: Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Apr 3;16(1):2900. [Abstract]; H&E staining showed that mice in the PLT treatment group (Paxlovid-like treatment: 56 mg/kg Nirmatrelvir, 19 mg/kg Ritonavir) exhibited mild to moderate multifocal inflammation, mainly confined to the peribronchial and perivascular areas of the lungs, with occasional alveolar collapse and mild hemorrhages.

: Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Nature. 2022 Jul;607(7917):119-127. [Abstract]; Syrian hamsters were intranasally inoculated with 103 PFU of BA.2 (NCD1288). One day after infection, hamsters were treated with: 500 mg kg−1 molnupiravir, 1,000 mg kg−1 nirmatrelvir or 60 mg kg−1 S-217622 orally twice daily for 3 days. Methylcellulose served as a control for oral treatment. Eight hamsters per group were euthanized at 4 dpi for virus titration. Viral titres in the nasal turbinates and lungs were determined by plaque assay.

: Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Sci Immunol. 2023 Apr 14;8(82):eadf0348. [Abstract]; DIO mice were infected with SARS-CoV-2 MA10 virus and treated with vehicle, Nirmatrelvir, or Nirmatrelvir plus MSDC. Host mortality was monitored and survival rate is shown.

: Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Sci Immunol. 2023 Apr 14;8(82):eadf0348. [Abstract]; DIO mice were infected with SARS-CoV-2 MA10 virus and treated with vehicle, Nirmatrelvir, or Nirmatrelvir plus MSDC. H&E staining of lung section (n = 5) and quantification of pathological lesions at 21 d.p.i. Scale bar, 200 μm. HM, hyaline membranes.

: Nirmatrelvir purchased from MedChemExpress. Usage Cited in: Vet Sci. 2023 Aug 9;10(8):513.; The CC₅₀, EC₅₀, and SI for six compounds against FIPV. The half-maximal cytotoxic concentration (CC₅₀) values are from four measurements of diluted drugs using MTT assay, in CRFK cells treated with drugs for 48 h. The half-maximal effective concentration (EC₅₀) values are from six measurements of diluted drugs against FIPV replication in CRFK cells for 48 h. Based on the SI value (mean CC₅₀)/(mean EC₅₀), GS-441524 was found highly selective (SI 165.5) against FIPV among the drugs tested and showed high efficacy (EC₅₀ 1.6 µM) against FIPV with a less deleterious effect (CC₅₀ 260.0 µM) on the cells. Nirmatrelvir also showed promising efficacy (EC₅₀ 2.5 µM) and selectivity (SI 113.7) against FIPV. Ritonavir showed the highest toxicity level in the cells (CC₅₀ 39.9).

: Nirmatrelvir purchased from MedChemExpress. Usage Cited in: N Engl J Med. 2023 Jan 5;388(1):89-91. [Abstract]; Remdesivir, Molnupiravir, and Nirmatrelvir are efficacious against both BQ.1.1 and XBB in vitro.

: Nirmatrelvir purchased from MedChemExpress. Usage Cited in: N Engl J Med. 2023 Jan 5;388(1):89-91. [Abstract]; Representative echocardiographic images (M-mode) from sham, TAC and Tipifarnib (10 mg/kg body weight/three times a week, IP injection) treated TAC mouse heart at 8 weeks.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 3CL^PRO^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	CC₅₀	> 100 μM Compound: Nirmatrelvir	Cytotoxicity against human CEM cells assessed as reduction in cell viability Cytotoxicity against human CEM cells assessed as reduction in cell viability	[PMID: 38432056]
Caco-2	CC₅₀	> 100 μM Compound: Nirmatrelvir	Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability Cytotoxicity against human Caco-2 cells assessed as reduction in cell viability	[PMID: 38432056]
Calu-3	CC₅₀	> 100 μM Compound: Nirmatrelvir	Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability Cytotoxicity against human Calu-3 cells assessed as reduction in cell viability	[PMID: 38432056]
Epithelial cell	EC₅₀	25.3 nM Compound: PF-07321332	Antiviral activity against SARS-CoV-2 infected in human Primary bronchial epithelial cell assessed as inhibition of viral growth Antiviral activity against SARS-CoV-2 infected in human Primary bronchial epithelial cell assessed as inhibition of viral growth	[PMID: 38335279]
HCT-8	CC₅₀	> 30 μM Compound: PF-07321332	Cytotoxicity against human HCT-8 cells incubated for 120 hrs by Cell-Titer Glo assay Cytotoxicity against human HCT-8 cells incubated for 120 hrs by Cell-Titer Glo assay	[PMID: 38335279]
HEK-293T	CC₅₀	> 50000 nM Compound: PF-07321332	Cytotoxicity against HEK293T cells transfected with ACE2 and TMPRSS2 assessed as reduction in cell viability Cytotoxicity against HEK293T cells transfected with ACE2 and TMPRSS2 assessed as reduction in cell viability	[PMID: 36229406]
HeLa	CC₅₀	> 40 μM Compound: PF-07321332	Cytotoxicity against human HeLa cells expressing ACE2 incubated for 120 hrs by Cell-Titer Glo assay Cytotoxicity against human HeLa cells expressing ACE2 incubated for 120 hrs by Cell-Titer Glo assay	[PMID: 38335279]
Huh-7	CC₅₀	> 100 μM Compound: Nirmatrelvir	Cytotoxicity against human Huh-7 cells overexpressing human ACE2 assessed as reduction in cell viability incubated for 24 hrs by MTT assay Cytotoxicity against human Huh-7 cells overexpressing human ACE2 assessed as reduction in cell viability incubated for 24 hrs by MTT assay	[PMID: 36549112]
Huh-7	CC₅₀	> 100 μM Compound: Nirmatrelvir	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability	[PMID: 38432056]
Huh-7	CC₅₀	> 50000 nM Compound: 4	Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 7 days by Celltiter -Glo assay Cytotoxicity against human Huh-7 cells assessed as reduction in cell viability measured after 7 days by Celltiter -Glo assay	[PMID: 38518735]
MRC5	CC₅₀	> 30 μM Compound: PF-07321332	Cytotoxicity against human MRC5 cells incubated for 120 hrs by Cell-Titer Glo assay Cytotoxicity against human MRC5 cells incubated for 120 hrs by Cell-Titer Glo assay	[PMID: 38335279]
MRC5	CC₅₀	> 50000 nM Compound: 4	Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 7 days by Celltiter -Glo assay Cytotoxicity against human MRC5 cells assessed as reduction in cell viability measured after 7 days by Celltiter -Glo assay	[PMID: 38518735]
MRC5	EC₅₀	0.212 μM Compound: Nirmatrelvir	Antiviral activity against against Human coronavirus 229E infected in human MRC5 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo luminescence assay Antiviral activity against against Human coronavirus 229E infected in human MRC5 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo luminescence assay	[PMID: 35971455]
PBMC	CC₅₀	> 100 μM Compound: Nirmatrelvir	Cytotoxicity against human PBMC cells assessed as reduction in cell viability Cytotoxicity against human PBMC cells assessed as reduction in cell viability	[PMID: 38432056]
Vero	CC₅₀	> 100 μM Compound: Nirmatrelvir	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability	[PMID: 38432056]
Vero	CC₅₀	> 25 μM Compound: Nirmatrevir	Cytotoxicity against african green monkey Vero cells Cytotoxicity against african green monkey Vero cells	[PMID: 36870624]
Vero C1008	CC₅₀	> 100 μM Compound: 1	Cytotoxicity against African green monkey Vero E6 cells incubated for 3 days by WST-8 assay Cytotoxicity against African green monkey Vero E6 cells incubated for 3 days by WST-8 assay	[PMID: 37756225]
Vero C1008	CC₅₀	> 100 μM Compound: 1	Cytotoxicity in African green monkey Vero E6 cells measured after 25 days by Neutral red release assay Cytotoxicity in African green monkey Vero E6 cells measured after 25 days by Neutral red release assay	[PMID: 37992202]
Vero C1008	CC₅₀	> 100 μM Compound: Nirmatrelvir	Cytotoxicity against african green monkey Vero E6 cells assessed as reduction in cell viability after 26 hrs by MTS assay Cytotoxicity against african green monkey Vero E6 cells assessed as reduction in cell viability after 26 hrs by MTS assay	[PMID: 36475694]
Vero C1008	CC₅₀	> 500 μM Compound: 1	Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against African green monkey Vero E6 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 37594952]
Vero C1008	CC₅₀	> 500 μM Compound: Nirmatrelvir	Cytotoxicity against African green monkey Vero E6 cells incubated for 48 hrs by Luminescent cell viability assay Cytotoxicity against African green monkey Vero E6 cells incubated for 48 hrs by Luminescent cell viability assay	[PMID: 37253309]
Vero C1008	CC₅₀	> 50000 nM Compound: PF-07321332	Cytotoxicity against African green monkey Vero E6 cells transfected with TMPRSS2 assessed as reduction in cell viability Cytotoxicity against African green monkey Vero E6 cells transfected with TMPRSS2 assessed as reduction in cell viability	[PMID: 36229406]
Vero C1008	EC₅₀	0.074 μM Compound: 1; PF-07321332	Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in viral growth incubated for 24 hrs by fluorescence based analysis Antiviral activity against SARS-CoV-2 infected in African green monkey Vero E6 cells assessed as reduction in viral growth incubated for 24 hrs by fluorescence based analysis	[PMID: 37244162]
Vero C1008	EC₅₀	0.075 μM Compound: Nirmatrelvir	Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in virus induced cytopathic effect incubated for 3 days Antiviral activity against SARS-CoV-2 infected in Vero E6 cells assessed as reduction in virus induced cytopathic effect incubated for 3 days	[PMID: 36475694]
Vero C1008	EC₅₀	0.729 μM Compound: 1	Antiviral activity against SARS-CoV-2 B1.617.2 (Delta) infected in african green monkey Vero E6 cells assessed as reduction in viral replication incubated for 24 hrs by qRT-PCR analysis Antiviral activity against SARS-CoV-2 B1.617.2 (Delta) infected in african green monkey Vero E6 cells assessed as reduction in viral replication incubated for 24 hrs by qRT-PCR analysis	[PMID: 37594952]
Vero C1008	EC₅₀	21.7 nM Compound: PF-07321332	Antiviral activity against SARS-CoV-2 variant Omicron BA.2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect Antiviral activity against SARS-CoV-2 variant Omicron BA.2 infected in African green monkey Vero E6 cells assessed as reduction in virus-induced cytopathic effect	[PMID: 37229831]
Vero C1008	EC₅₀	75 nM Compound: 13	Antiviral activity against SARS Cov-2 infected in Vero E6 cells expressing hACE2 assessed as virus induced cytopathic effect incubated for 3 day by Cell Titer-Glo assay Antiviral activity against SARS Cov-2 infected in Vero E6 cells expressing hACE2 assessed as virus induced cytopathic effect incubated for 3 day by Cell Titer-Glo assay	[PMID: 35291756]

In Vitro

3CL^PRO is responsible for cleaving polyproteins 1a and 1ab of SARS-CoV-2.1. Without the activity of the SARS-CoV-2 3CL^PRO, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

499.53

Formula

C₂₃H₃₂F₃N₅O₄

CAS No.

2628280-40-8

Appearance

Solid

Color

White to off-white

SMILES

O=C(NCC1)[C@@H]1C[C@@H](C#N)NC([C@@H]2[C@]3([H])[C@@](CN2C([C@H](C(C)(C)C)NC(C(F)(F)F)=O)=O)([H])C3(C)C)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 140 mg/mL (280.26 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 50 mg/mL (100.09 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.0019 mL	10.0094 mL	20.0188 mL
5 mM	0.4004 mL	2.0019 mL	4.0038 mL
10 mM	0.2002 mL	1.0009 mL	2.0019 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.16 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.74%

Select Batch:

Data Sheet (280 KB) SDS (394 KB)

COA (260 KB) HNMR (283 KB) RP-HPLC (329 KB) Elemental Analysis Report (116 KB)

Handling Instructions (2659 KB)

References

[1]. KoenVandyck, et al. Considerations for the Discovery and Development of 3-Chymotrypsin-Like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection. Current Opinion in Virology Available online 27 April 2021

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	2.0019 mL	10.0094 mL	20.0188 mL	50.0470 mL
	5 mM	0.4004 mL	2.0019 mL	4.0038 mL	10.0094 mL
	10 mM	0.2002 mL	1.0009 mL	2.0019 mL	5.0047 mL
	15 mM	0.1335 mL	0.6673 mL	1.3346 mL	3.3365 mL
	20 mM	0.1001 mL	0.5005 mL	1.0009 mL	2.5024 mL
	25 mM	0.0801 mL	0.4004 mL	0.8008 mL	2.0019 mL
	30 mM	0.0667 mL	0.3336 mL	0.6673 mL	1.6682 mL
	40 mM	0.0500 mL	0.2502 mL	0.5005 mL	1.2512 mL
	50 mM	0.0400 mL	0.2002 mL	0.4004 mL	1.0009 mL
	60 mM	0.0334 mL	0.1668 mL	0.3336 mL	0.8341 mL
	80 mM	0.0250 mL	0.1251 mL	0.2502 mL	0.6256 mL
	100 mM	0.0200 mL	0.1001 mL	0.2002 mL	0.5005 mL

Nirmatrelvir Related Classifications

Inflammation/Immunology Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nirmatrelvir2628280-40-8PF-07321332PF07321332PF 07321332SARS-CoVSARS coronavirus3CLPROHIVSARS-CoV-2virusAntiviralInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Nirmatrelvir (Synonyms: PF-07321332)

Customer Review

Other Forms of Nirmatrelvir:

Nirmatrelvir Related Antibodies

103 Publications Citing Use of MCE Nirmatrelvir

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Nirmatrelvir Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Nirmatrelvir Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report